Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View PlansCash Conversion
0.97x
TORNTPHARM's operating cash flow covered 97% of net income in FY 2025. Some earnings may be tied up in working capital.
Free Cash Flow
₹19.73B
TORNTPHARM's free cash flow was ₹19.73B in FY 2025, down 30.3% from FY 2024.
Dividend Coverage
1.8x
TORNTPHARM's free cash flow covered dividends 1.8x in FY 2025 but leaves limited surplus.
CapEx Intensity
23.7%
Capital expenditure was 23.7% of operating cash flow in FY 2025 for TORNTPHARM, indicating a capital-light business.
Hover the chart icon for YoY change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Net Income | 23.52B | 26.73B | |
| Cash flow Operating Activities | 32.66B | 25.85B | |
| Investments in PPE | -4.33B | -6.12B | |
| Cash flow Investing Activities | -1.68B | -5.40B | |
| Dividend Paid | -10.15B | -10.83B | |
| Cash flow Financing Activities | -27.79B | -22.98B | |
| Cash at beginning of period | 5.08B | 8.35B | |
| Cash at end of period | 8.35B | 5.73B | |
| Free Cash Flow | 28.33B | 19.73B |
Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025